3 Psychedelic Sector Leaders That Investors Need To Be Aware OfPsyched Wellness Announces New OTCQB Ticker: PSYCF2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private Placement

MindMed Is Setting The Pace For Top Tier Psychedelics Stocks

Nov 3, 2020 • 10:39 AM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

MindMed (NEO: MMED, OTCQB: MMEDF) is considered to be one of the top psychedelic therapy biotech companies and is an opportunity that our readers should be aware of.

Last week, the psychedelic therapy biotech company recorded volatile price movements after raising more than $28 million (CAD) through a private placement of units. MindMed plans to use the proceeds from the capital raise to execute on a series of clinical trials that are in various stages of testing.

One of the key differentiators for MindMed is its partnership with University Hospital Basel’s Liechti Lab and we are bullish on this aspect of the story. Earlier this week, MindMed reported to have completed and published a Phase 1 study on the acute dose dependent effects of lysergic acid diethylamide (LSD). The completion of the study will help the company in the dosing and planning of Phase 2 clinical trials on patients who have anxiety disorders and other medical conditions.

The Phase 1 study measured LSD induced responses from patients and started at microdoses (25ug) and went up to experiential doses (200ug). Although the company reported the best effects with a 100ug dose, an experiential dose of 200ug was shown to induce greater ego dissolution. This is important because ego-dissolution is considered to be one of the core therapeutic potentials of the psychedelic experience and psychedelic assisted therapy process.

Following the results, MindMed’s team is working tirelessly on the preparation of Project Lucy. The project is expected to evaluate the efficacy of LSD assisted therapy for anxiety disorders in a Phase 2b clinical trial and we will monitor how the management team is able to execute.

The completion of the study is considered to be an important steppingstone for MindMed. Going forward, the company plans to use the data to support Project Lucy as the team identifies optimal dose levels of LSD to test in the Phase 2b trial of anxiety disorders.

MindMed and University Hospital Basel are actively filing patent applications on clinical trial data that was generated through the collaboration’s clinical trials and R&D. We consider the relationship to be an attractive aspect of the story and will monitor how the companies are able to execute on clinical trials. MindMed has an exclusive license to the data and IP that is generated through the research collaboration and licensing agreement with the Liechti Lab at University Hospital Basel.

Going forward, we believe that MindMed is well positioned to execute on several major growth projects and will monitor how the management team continues to drive the story forward. If you are interested in learning more about the psychedelic therapy biotech company, please send an email to support@mushroomstocks.com with the subject “MindMed” to be added to our distribution list.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.